bioAffinity Technologies, Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
bioAffinity Technologies reported 109% year-to-date growth in CyPath Lung test unit sales through Q3 2026, with 89% increase in ordering physicians and 48% growth from repeat customers. The company raised $4M via registered direct offering at market prices in October 2026. New distribution agreement with AvMEDICAL provides access to VA medical centers and federal healthcare facilities nationwide; this partnership does not itself represent completed sales. Company also expanded patent portfolio in Hong Kong, China, and Japan, and is advancing asthma/COPD diagnostic development.
Why this rating
109% test growth and $4M funding are material for $22.6M market-cap company; VA partnership opens significant new channel. Early-stage pipeline risk remains; commercialization trajectory is promising but unproven.
Tradability signal
NO TRADE
No trade: price $0.15 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.15 | +10 min · unknown $0.15 ▼ 0.79% | +30 min · unknown $0.15 ▼ 0.79% | +1 hr · unknown $0.15 ▼ 0.79% | +4 hrs · unknown $0.15 ▼ 0.79% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.